Biohaven Ltd


Biohaven Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.52
  • Today's Change0.45 / 2.99%
  • Shares traded900.52k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (OCD) and Spinocerebellar Ataxia (SCA), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for immune-mediated brain disorders. Its portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE) with potential application in neurological disorders, cancer, and autoimmune diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-543.74m
  • Incorporated--
  • Employees202.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Mirum Pharmaceuticals Inc95.77m-129.19m993.77m200.00--7.04--10.38-3.65-3.652.703.710.31313.645.89488,612.30-42.24---48.91--84.41---134.90--3.39-13.250.00--302.66---61.53------
POINT Biopharma Global Inc236.04m98.14m994.57m129.0012.132.119.964.210.77570.77572.364.460.5817--1,895.271,829,743.0024.19--27.26------41.58------0.00------314.13------
Adaptive Biotechnologies Corp184.34m-195.15m997.19m790.00--2.35--5.41-1.36-1.361.292.940.22353.106.89233,335.40-23.67-17.18-27.04-19.0765.6170.34-105.93-115.585.34-202.410.2305--20.0636.963.42--45.51--
VectivBio Holding AG0.00-93.74m1.02bn42.00--4.79-----1.87-1.870.003.400.00----0.00-48.18---53.99-------------6.140.0467-------7.73------
Viridian Therapeutics Inc1.65m-172.33m1.02bn86.00--4.74--618.82-4.66-4.660.04588.140.0058--5.0919,232.56-60.49-58.44-65.55-64.13-----10,419.11-2,117.74----0.0132---40.20-15.04-63.54--26.50--
Inhibrx Inc1.28m-162.89m1.05bn141.00--69.60--823.25-3.94-3.940.0310.34710.0062--3.769,078.02-78.52-79.44-89.96-103.32-----12,725.63-872.80---7.610.9307---69.69-23.55-77.61---12.53--
Biohaven Ltd0.00-543.74m1.06bn202.00--2.24-----8.15-
Avadel Pharmaceuticals PLC (ADR)0.00-141.82m1.06bn41.00---------2.33-2.330.00-0.59190.00----0.00-78.38-31.61-118.94-37.90-------187.05---6.991.51-------77.77---57.83--
National Research Corporation149.60m30.21m1.07bn491.0035.7014.2729.967.,684.3021.0326.4628.8237.6962.2062.8820.2024.83--80.380.220151.892.445.21-15.128.7815.3416.00
Deciphera Pharmaceuticals Inc138.26m-181.65m1.08bn300.00--2.46--7.83-2.35-2.351.795.610.29590.39316.07460,860.00-38.88-44.40-47.56-50.9493.58---131.38-349.015.37--0.00--39.41--40.35--15.68--
P3 Health Partners Inc1.08bn-268.75m1.09bn600.00------1.01-6.46-6.4625.93-0.0110.6687--11.411,796,673.00-96.35---628.63--0.0956---144.08-----17.960.1867--64.66---72.63------
Opko Health Inc.912.55m-291.24m1.09bn4.20k--0.702--1.19-0.3951-0.39511.232.010.40776.985.46217,481.90-13.00-6.47-14.75-7.4033.1134.81-31.87-12.721.49-20.170.1413---43.420.7785-989.49---11.98--
Taro Pharmaceutical Industries Ltd572.95m25.44m1.10bn1.46k43.410.766119.191.930.6770.67715.2438.360.26581.392.55--1.181.851.462.2146.8356.824.446.992.88------2.07-2.85-56.33-34.53-9.58--
Immunitybio Inc586.00k-430.08m1.11bn703.00------1,889.76-1.05-1.050.0014-1.210.0016--0.2188808.28-117.58-94.40---212.70-----73,533.27-30,976.64---5.893.86---74.3039.77-20.12--23.34--
NewAmsterdam Pharma Company NV104.56m-83.70m1.11bn17.00--2.14--10.62-1.02-,150,516.00-------------80.05-----0.37540.0002-------172.92------
Biomea Fusion Inc0.00-94.51m1.11bn83.00--11.21-----3.21-
Data as of May 26 2023. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD

Institutional shareholders

55.06%Per cent of shares held by top holders
HolderShares% Held
1919 Investment Counsel LLCas of 31 Mar 20235.62m8.24%
Janus Henderson Investors US LLCas of 31 Mar 20235.23m7.66%
SSgA Funds Management, Inc.as of 31 Mar 20234.55m6.67%
Suvretta Capital Management LLCas of 31 Mar 20233.85m5.64%
BlackRock Fund Advisorsas of 31 Mar 20233.83m5.62%
Fidelity Management & Research Co. LLCas of 31 Mar 20233.65m5.36%
Armistice Capital LLCas of 31 Mar 20233.12m4.58%
RP Management LLC (Investment Management)as of 31 Mar 20232.94m4.31%
Point72 Asset Management LPas of 31 Mar 20232.72m3.99%
Holocene Advisors, LPas of 31 Mar 20232.04m3.00%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.